These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35046801)

  • 21. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
    Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
    Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel
    Zhi X; Luo J; Li W; Wang J; Wang Y; Cai Y; Yan X
    Front Oncol; 2021; 11():733276. PubMed ID: 34760695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis.
    Botrel TE; Clark O; Clark L; Paladini L; Faleiros E; Pegoretti B
    Lung Cancer; 2011 Oct; 74(1):89-97. PubMed ID: 21377753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective cohort study of patients with non-squamous non-small cell lung cancer treated with bevacizumab.
    Naoki K; Takeda Y; Soejima K; Arai D; Naka G; Nagase S; Arimura K; Kanemura T; Ohhira T; Ikeda N
    Oncol Lett; 2017 May; 13(5):3285-3290. PubMed ID: 28521435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The optimal timing and courses of bevacizumab added to chemotherapy for non-squamous non-small cell lung cancer: revelations from the real-world experience in a single Chinese cancer center.
    Long Q; Feng Y; Liu C; Wu X; Wang H; Yu H; Zhao X; Wang J
    Ann Transl Med; 2020 Oct; 8(20):1311. PubMed ID: 33209891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients.
    Jiang T; Li A; Su C; Li X; Zhao C; Ren S; Zhou C; Zhang J
    Oncotarget; 2017 Sep; 8(37):62648-62657. PubMed ID: 28977977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy.
    Osumi H; Shinozaki E; Ooki A; Wakatsuki T; Kamiimabeppu D; Sato T; Nakayama I; Ogura M; Takahari D; Chin K; Yamaguchi K
    Cancer Med; 2021 Jan; 10(2):615-625. PubMed ID: 33347731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure.
    Lam TC; Tsang KC; Choi HC; Lee VH; Lam KO; Chiang CL; So TH; Chan WW; Nyaw SF; Lim F; Lau JO; Chik J; Kong FM; Lee AW
    Lung Cancer; 2021 Sep; 159():18-26. PubMed ID: 34303276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis.
    Tsai JS; Su PL; Yang SC; Chang CC; Lin CY; Yen YT; Tseng YL; Lai WW; Lin CC; Su WC
    J Formos Med Assoc; 2021 Sep; 120(9):1729-1739. PubMed ID: 33865672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
    Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
    Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.
    Chen WC; Qiu JT; Lai CH; Huang HJ; Lin CT; Chen MY; Chou HH; Huang KG; Chang TC
    PLoS One; 2017; 12(5):e0175703. PubMed ID: 28467466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
    Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
    Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
    Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
    Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial.
    Hibino M; Hiranuma O; Takemura Y; Katayama Y; Chihara Y; Harada T; Fujita K; Kita T; Tamiya N; Tsuda T; Shiotsu S; Tamura Y; Aoyama T; Nakamura Y; Terashima M; Morimoto Y; Nagata K; Yoshimura K; Uchino J; Takayama K
    JTO Clin Res Rep; 2022 Dec; 3(12):100424. PubMed ID: 36438852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.
    Zinner RG; Obasaju CK; Spigel DR; Weaver RW; Beck JT; Waterhouse DM; Modiano MR; Hrinczenko B; Nikolinakos PG; Liu J; Koustenis AG; Winfree KB; Melemed SA; Guba SC; Ortuzar WI; Desaiah D; Treat JA; Govindan R; Ross HJ
    J Thorac Oncol; 2015 Jan; 10(1):134-42. PubMed ID: 25371077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.
    Pujol JL; Lavole A; Quoix E; Molinier O; Souquet PJ; Barlesi F; Le Caer H; Moro-Sibilot D; Fournel P; Oster JP; Chatellain P; Barre P; Jeannin G; Mourlanette P; Derollez M; Herman D; Renault A; Dayen C; Lamy PJ; Langlais A; Morin F; Zalcman G;
    Ann Oncol; 2015 May; 26(5):908-914. PubMed ID: 25688059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
    Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
    Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation.
    Li Y; Wang Y; Niu K; Chen X; Xia L; Lu D; Kong R; Chen Z; Duan Y; Sun J
    Oncotarget; 2016 Oct; 7(43):70535-70545. PubMed ID: 27655708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation.
    Yoshimura A; Yamada T; Okura N; Takeda T; Hirose K; Kubota Y; Shiotsu S; Hiranuma O; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
    Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30875919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study.
    Artaç M; Coşkun HŞ; Dane F; Karabulut B; Korkmaz L; Karaağaç M; Çabuk D; Karabulut S; Faruk Aykan N; Doruk H; Avcı N; Turhal NS
    J Gastrointest Cancer; 2016 Sep; 47(3):264-72. PubMed ID: 27126591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.